Pfizer Inc. (NYSE:PFE) announced today that it will present data from a
Phase 1/Phase 2 study evaluating the safety, tolerability and
immunogenicity of a single-dose vaccine of Pfizer’s investigational
4-antigen Staphylococcus aureus ( S.
for Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™ investment picks